Aptinyx Inc.

Company Listings from SPi: Aptinyx Inc.

You are here: Home >> SPi Company Listings >> Aptinyx Inc.

 

Aptinyx Inc.

Website:
http://

Search for other references to "aptinyx" on SPi News

Latest Aptinyx Inc. News

Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy EVANSTON, Ill., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 12:27 GMT Wednesday 16th January 2019

Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment o...... 13:07 GMT Wednesday 2nd January 2019

Aptinyx to Present Preclinical Data on NMDA Receptor Modulator NYX-2925 at the American College of Neuropsychopharmacology’s Annual Meeting EVANSTON, Ill., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 13:27 GMT Tuesday 11th December 2018

Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference EVANSTON, Ill., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment o...... 13:07 GMT Wednesday 5th December 2018

Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia EVANSTON, Ill., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 12:27 GMT Monday 3rd December 2018

Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights EVANSTON, Ill., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 12:27 GMT Tuesday 13th November 2018

Aptinyx Exploratory Clinical Studies Provide First Evidence that NYX-2925 Elicits Rapid, Persistent, NMDAr-Mediated Pharmacodynamic Activity in Humans EVANSTON, Ill., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment o...... 12:07 GMT Monday 12th November 2018

Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy EVANSTON, Ill., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 11:27 GMT Thursday 1st November 2018

Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience EVANSTON, Ill., Oct. 29, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of...... 12:07 GMT Monday 29th October 2018

Aptinyx to Present at Cantor Fitzgerald Global Healthcare Conference EVANSTON, Ill., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and ne...... 21:01 GMT Tuesday 25th September 2018

Buy Aptinyx Inc.
Market Reports
from SPi

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us